Company / SG&A Expense
AtriCure, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$311.0M
FY2025
5-year range
$204.6M / $311.0M
FY2021-FY2025
Trend
+6.7%
vs FY2024
Sector context
#85 of 152
Health Care
What the data says
At $311M, AtriCure, Inc.'s sg&a expense ranks #68 of 152 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $151M in FY2020 to $311M in FY2025.
Based on SEC 10-K filings.
$311M in FY2025 with a 5-year CAGR of +15.6%.
Increased from $253M to $311M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- +15.6%
- 10-Year CAGR
- -
Sector benchmark
#68 of 152 in Health CareTop 44% of 152This company $311.0M Sector average $182.7B
▼
-99.8% below sector average
Key checks
Key Insights
- AtriCure, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +15.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 6.7% year-over-year.
- Ranks #85 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -9.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $311.0M | +6.7% |
| FY2024 | $291.4M | +15.1% |
| FY2023 | $253.1M | +9.5% |
| FY2022 | $231.3M | +13.0% |
| FY2021 | $204.6M | +35.7% |
| FY2020 | $150.8M | -9.8% |
| FY2019 | $167.1M | +29.0% |
| FY2018 | $129.5M | +10.7% |
| FY2017 | $117.0M | +9.9% |
| FY2016 | $106.4M | +13.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026